Showing 1451-1460 of 1550 results for "".
- Three Dermal Filler Patients Had Adverse Reactions to the Moderna COVID-19 Vaccinehttps://practicaldermatology.com/news/three-filler-patients-had-adverse-reactions-to-the-moderna-covid-19-vaccine/2460642/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Breaking News: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://practicaldermatology.com/news/breaking-news-abbvies-allergan-wins-trade-secret-case-against-evolus/2460635/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- High Kissability Marks for Restylane Kysse in New Phase 4 Studyhttps://practicaldermatology.com/news/high-kissability-marks-for-restylane-kysse-in-new-phase-4-study/2460465/In a recent first-of-its-kind phase IV, Kissability study for an injectable hyaluronic acid (HA) lip filler, subject satisfaction as well as partner satisfaction were evaluated following treatment with Restylane Kysse. Many consumers report they often keep their lip treatments a
- Physician-Created App Unveils Remote Check-In Feature to Prevent Spread of COVID-19 in Medical Practiceshttps://practicaldermatology.com/news/physician-created-app-unveils-remote-check-in-feature-to-prevent-spread-of-covid-19-in-medical-practices/2460436/DocClocker, an app that allows patients to receive real-time wait time reporting of their medical providers, enabling patients to avoid long waits in medical waiting rooms—limiting COVID-19 exposure risks. The company recently launched a new feature for the app—DocClocker Remote Check
- AAD Survey: Most Americans Know Sun Protection Is Important, Still Don't Protect Themselveshttps://practicaldermatology.com/news/aad-survey-most-americans-know-sun-protection-is-important-but-still-dont-protect-themselves-1/2460367/Fully 76 percent of Americans agree that sun protection is an important healthy habit, yet only 41 percent report regularly protecting themselves outdoors — increasing their risk for skin cancer, according to a new survey from the American Academy of Dermatology. What’s more
- Lessons from Italy: Understanding and Recognizing Potential Skin Manifestations in COVID-19https://practicaldermatology.com/news/lessons-from-italy-understanding-and-recognizing-potential-skin-manifestations-in-covid-10-1/2460340/Italian dermatologists report that about 20 percent of COVID-19 patients may develop skin manifestations including red rashes. Their findings appear in Journal of the European Academy of Dermatology Venereology. The researchers looked at skin in 148 COVID-19 patients
- Dermatologists React to Threat of Coronavirus Pandemichttps://practicaldermatology.com/news/dermatologists-react-to-threat-of-coronavirus-pandemic/2460291/Reports about COVID-19 are causing many dermatologists to rethink their travel plans and update their office policy on the care of sick patients. The International Health Regulations Emergency Committee of the World Health Organization declared the outbreak a “public health emerge
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- Keloid Breakthrough: Mount Sinai Researchers Show Keloid Shrinkage with Dupilumabhttps://practicaldermatology.com/news/keloid-breakthrough-mount-sinai-researchers-show-keloid-shrinkage-with-dupilumab/2460223/Keloid lesions exhibit increased IL-4/IL-13 signaling and respond to Th2-targeting dupilumab therapy, Mount Sinai researchers report. Researchers, led by Emma Guttman-Yassky, MD, PhD, Vice Chair, Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York,
- UCB’s Bimekizumab Performs Well in Phase 3 Psoriasis Studyhttps://practicaldermatology.com/news/ucbs-bimekizumab-performs-well-in-phase-3-psoriasis-study/2460186/UCB’s bimekizumab, an IL-17A and IL-17F inhibitor, bested placebo and Stelara (ustekinumab) when it came to clearing the skin of patients with moderate-to-severe chronic plaque psoriasis and improving their symptoms, the company reports. BE VIVID is the first of three Phase 3